Dr. Joan M. Freesh, a highly respected veterinarian and former president of the Missouri Veterinary Medical Association, recently shared a poignant account of her personal experience treating her beloved calico cat, Gryphin, for nasal lymphoma. This narrative, originally published on September 23, 2025, highlights the complexities of feline cancer diagnosis and treatment, underscoring the critical importance of specialist intervention and ongoing research in veterinary oncology. Dr. Freesh’s story serves as a powerful testament to the advancements in veterinary medicine and the profound bond between humans and their animal companions, particularly when facing serious health challenges. The Unforeseen Arrival of Gryphin: A Rescue Story Gryphin’s journey into Dr. Freesh’s life began in an unexpected manner. One day, a friend and client contacted Dr. Freesh after discovering a tiny calico kitten crying distressed in a sinkhole within Blackburn Park, a well-known green space in Webster Groves, Missouri. Dr. Freesh, whose feline practice was renowned for taking in rescued and found cats, providing them with comprehensive care, and facilitating adoptions to loving homes, immediately responded to the call. Upon seeing the kitten at Rick and Susan’s home, Dr. Freesh, captivated by the mostly black calico, made the instant decision to bring her home. This initial act of compassion marked the beginning of a remarkable 16-year companionship. The kitten was named Gryphin by Dr. Freesh’s oldest son, Jared, a name that would soon become synonymous with a vibrant and distinctive personality. Gryphin quickly revealed a unique character, exhibiting behaviors that charmed her human family. She possessed an unusual fascination with water, often sitting patiently in a filling bathtub, seemingly mesmerized as the water level rose around her. Another peculiar habit involved sunbathing on the patio, stretched out on her back, allowing her belly to soak up the warmth of the sun. These endearing quirks solidified her place as a cherished member of the Freesh household, making her subsequent health challenges all the more impactful. A Diagnosis of Nasal Lymphoma: Professional Acumen Meets Personal Concern Gryphin lived a healthy and joyful life for 13 years before the onset of concerning symptoms. At this age, Dr. Freesh observed ocular and nasal discharge originating from Gryphin’s right side. As a seasoned veterinarian with decades of experience, Dr. Freesh initially treated Gryphin with antibiotics, suspecting a common infection. However, when the symptoms persisted and showed no improvement, her professional instincts led her to consider a more serious underlying condition: nasal lymphoma. Feline lymphoma is the most common cancer diagnosed in cats, accounting for approximately 30% of all feline cancers. It originates from lymphocytes, a type of white blood cell, and can affect various organs, including the gastrointestinal tract, mediastinum, kidneys, and nasal cavity. Nasal lymphoma, while less common than the gastrointestinal form, presents its own unique challenges due to its location, which can impede breathing and cause ocular symptoms. Given her suspicion, Dr. Freesh sought specialized expertise. She referred Gryphin to a trusted colleague and friend, a specialist in veterinary oncology, for advanced diagnostic procedures. This referral underscored Dr. Freesh’s commitment to providing the best possible care, even for her own pet, and highlighted the importance of collaborative veterinary medicine. The specialist performed a rhinoscopy, a procedure involving the insertion of a small, flexible plastic tube equipped with fiber optics into the nasal passages to visually inspect the airway. This was followed by a biopsy, where tissue samples were collected for histopathological examination. The subsequent diagnosis confirmed Dr. Freesh’s suspicion: Gryphin had nasal lymphoma. Understanding Feline Lymphoma and the CHOP Protocol The diagnosis of cancer in a beloved pet is devastating for any owner, and even for a veterinarian, it brings a unique blend of professional understanding and personal anguish. Feline lymphoma is broadly classified into several types based on anatomical location and cell type (T-cell or B-cell). Nasal lymphoma typically presents with signs such as chronic nasal discharge, sneezing, epistaxis (nosebleeds), facial swelling, and ocular discharge. Early diagnosis is crucial for better outcomes. Treatment for feline lymphoma, particularly the nasal form, often involves chemotherapy. One of the most common and effective chemotherapy protocols used in veterinary oncology is the CHOP protocol. This acronym represents a combination of four potent chemotherapeutic agents: Cyclophosphamide: An alkylating agent that interferes with DNA replication, thereby inhibiting cancer cell growth. Hydroxydaunorubicin (Doxorubicin): An anthracycline antibiotic that intercalates DNA, leading to DNA damage and apoptosis in cancer cells. Oncovin (Vincristine): A vinca alkaloid that inhibits microtubule formation, disrupting cell division. Prednisone: A corticosteroid that not only has direct lympholytic effects (killing lymphoma cells) but also helps manage inflammation and side effects of other chemotherapies. The CHOP protocol is typically administered over several weeks or months, with cycles designed to maximize efficacy while minimizing side effects. For nasal lymphoma, studies have shown that cats treated with chemotherapy can achieve remission periods ranging from one to three years, significantly improving their quality of life and extending their lifespan. The success rates vary depending on the stage of the cancer, the cat’s overall health, and the specific type of lymphoma. However, the potential for long-term remission offers a beacon of hope for pet owners facing such a diagnosis. Gryphin’s Remarkable Remission and Extended Life Following the diagnosis, Dr. Freesh, leveraging her expertise and informed by specialist advice, initiated the CHOP chemotherapy protocol for Gryphin. The treatment proved highly effective. All of Gryphin’s symptoms resolved completely, marking a successful entry into remission. This period of remission was not just a medical success; it represented a precious extension of Gryphin’s life, allowing her to continue enjoying her unique personality and bond with her family. Gryphin lived a vibrant life for a little over three years in remission, thriving well beyond the typical expectation for feline nasal lymphoma. Her extended period of health and happiness, living to be 16 years old, underscored the profound impact of timely diagnosis, advanced veterinary care, and the dedicated efforts of her veterinarian owner. This outcome not only brought joy to Dr. Freesh and her family but also provided a powerful, real-world example of the efficacy of modern veterinary oncology. The Difficult Decision: Recurrence and Quality of Life At 16 years of age, Gryphin’s lymphoma unfortunately came out of remission. The recurrence of cancer, coupled with other age-related health issues that had begun to develop, presented Dr. Freesh with an incredibly difficult decision. While the initial chemotherapy had granted Gryphin several additional years of quality life, the prospects for a second round of aggressive treatment were considerably different. In veterinary oncology, the decision to pursue further treatment after a recurrence involves a complex evaluation of multiple factors: the cat’s current health status, the aggressiveness of the recurring cancer, the potential for achieving a meaningful remission, and critically, the anticipated quality of life during and after treatment. For an elderly cat like Gryphin, at 16 years old with additional health problems, the physical and emotional toll of another intensive chemotherapy regimen would be substantial, with a lower probability of success compared to the initial treatment. Dr. Freesh reflected positively on her decision to treat Gryphin initially, acknowledging the significant extension of her life and the quality she enjoyed during remission. However, she recognized that continuing aggressive treatment at this stage might compromise Gryphin’s comfort and dignity without a high likelihood of a positive outcome. With profound love and professional judgment, Dr. Freesh made the compassionate decision not to pursue further chemotherapy. Instead, she chose to provide Gryphin with a peaceful and dignified transition, allowing her to "go to kitty heaven." This decision, while heartbreaking, reflected Dr. Freesh’s ultimate commitment to Gryphin’s well-being and a deep understanding of the delicate balance between extending life and preserving quality of life in advanced stages of illness. A Call to Action for Pet Owners: Seek Specialist Care Dr. Freesh’s experience with Gryphin culminates in a vital message for all cat owners: "Anyone faced with a cancer diagnosis for their cat should know there are options and they should seek a specialist." This statement is not merely advice but a call to action rooted in decades of professional practice and personal experience. The field of veterinary oncology has advanced dramatically, offering a growing array of diagnostic tools, treatment protocols, and palliative care options. Early detection often leads to more effective treatment and better prognoses. Veterinary oncologists possess specialized knowledge and experience in diagnosing and managing various cancers, providing tailored treatment plans that consider the specific type of cancer, its stage, and the individual pet’s overall health and temperament. They can offer insights into chemotherapy, radiation therapy, surgery, and newer immunotherapies, guiding owners through complex decisions. Furthermore, specialists can provide invaluable support in managing the side effects of treatment, ensuring the pet’s comfort throughout the process. They also play a crucial role in discussing prognosis, quality of life, and end-of-life care planning, helping owners make informed and compassionate choices. The financial implications of specialized care are often a concern for pet owners, but many veterinary oncologists and clinics offer various options and discuss cost-effective approaches. Dr. Joan M. Freesh: A Legacy in Feline Veterinary Medicine Dr. Joan M. Freesh’s account of Gryphin’s battle with lymphoma is enriched by her distinguished career in veterinary medicine. Her deep interest in science and medicine blossomed early, leading her to The University of Tennessee (Knoxville), where she earned a BS in Animal Husbandry in 1970 and an MS in Zoology in 1975. She further pursued her passion, graduating from Auburn University with a Doctor of Veterinary Medicine degree in 1977. Dr. Freesh quickly established herself as a leader in her field. In 1993, she made history by being elected as the first woman president of the Missouri Veterinary Medical Association, a significant achievement that broke barriers and inspired many. Her commitment to feline health led her to found the St. Louis Cat Clinic in 1992, a pioneering practice dedicated exclusively to the care of cats. She owned and operated the clinic until her retirement in 2019, building a legacy of excellence and compassionate care for countless feline patients and their owners. Dr. Freesh often cherishes her time as an owner of a feline practice and her interactions with numerous cats and cat owners over the years, experiences that undoubtedly informed her approach to Gryphin’s care. The Indispensable Role of Research: EveryCat Health Foundation Dr. Freesh concluded her reflection by expressing gratitude to the EveryCat Health Foundation for its support of research into feline cancers. This acknowledgment highlights a critical component in the ongoing fight against diseases like lymphoma: sustained research funding. Organizations like EveryCat Health Foundation are instrumental in advancing veterinary medicine by funding studies that investigate the causes, diagnostics, treatments, and prevention of various feline diseases, including cancer. Research supported by such foundations leads to breakthroughs in understanding cancer biology, developing new and more effective chemotherapy agents, improving diagnostic techniques, and exploring novel therapies such as targeted drugs and immunotherapies. For instance, ongoing research aims to identify genetic markers that predict treatment response or disease progression, allowing for more personalized medicine. Without dedicated funding, the progress seen in veterinary oncology, which directly translated into Gryphin’s extended life, would not be possible. These foundations often collaborate with leading veterinary colleges and research institutions, ensuring that funds are directed towards high-impact projects that promise to improve the lives of cats globally. Their work is a testament to the collective effort required to push the boundaries of animal health and welfare. Broader Implications and the Future of Feline Oncology Dr. Freesh’s story of Gryphin is more than just a personal anecdote; it is a powerful narrative with broader implications for the veterinary community and pet owners alike. It underscores the advancements in veterinary oncology, which now allow for significant extensions of life and improved quality of life for pets diagnosed with cancer. It reinforces the ethical considerations inherent in veterinary practice, particularly the balance between aggressive treatment and ensuring a dignified end-of-life experience. As veterinary medicine continues to evolve, the emphasis on specialized care, personalized treatment plans, and a holistic approach to pet health will only grow. The increasing human-animal bond means that pet owners are often willing to pursue advanced medical care for their companions, mirroring trends in human medicine. This commitment, combined with the dedication of professionals like Dr. Freesh and the vital work of research foundations, paints a hopeful picture for the future of feline oncology, promising even better outcomes for cats facing cancer in the years to come. The enduring memory of Gryphin, with her sweet disposition and quirky behavior, serves as a poignant reminder of the profound love and care that defines the relationship between pets and their human families, a bond that Dr. Freesh has dedicated her entire career to honoring and protecting. Post navigation The Silent Suffering: Anna’s Story Uncovers Critical Gaps in Animal Welfare and Inspires Advocacy Actor Joey Luthman Embarks on Cross-Country One-Wheel Journey to Fund Feline Chronic Kidney Disease and Cancer Research
